Background: One major barrier to successful xenotransplantation is acute vascular rejection, a process
. Hyperacute rejection is characterized pathologically by interstitial edema, hemorrhage, and platelet thrombi resulting from loss of endothelial function and integrity (1, 3, 4) . Hyperacute rejection can be prevented through the depletion of xenoreactive antibodies (5) or partial inhibition of complement activation (6, 7) . Recent work in our laboratory has demonstrated that depletion of host anti-graft antibodies or the inhibition of complement activation increases xenograft survival in porcine-to-baboon transplants (8) (9) (10) . When hyperacute rejection is avoided, the graft often succumbs to "acute vascular rejection," which is characterized pathologically by endothelial injury, focal ischemia, and diffuse microvascular fibrin deposition and thrombosis (11) .
Fibrin is the physiological endproduct of the coagulation cascade that is formed in response to vascular injury. In the final step of the coagulation pathway, thrombin converts fibrinogen to fibrin, which forms the biochemical matrix that composes occlusive vascular thrombi. Vascular patency is restored via the proteolytic breakdown of fibrin via a series of complex interactions between serine proteases and their inhibitors. Thus, fibrin is degraded by the protease plasmin which is formed from its inactive zymogen, plasminogen. The main biological plasminogen activator, tissue plasminogen activator, is secreted from endothelial cells (12, 13) and is involved in the dissolution of fibrin in both normal physiologic and disease states (14) . Inhibitors of plasmin generation act by inhibiting plasminogen activators, of which plasminogen activator inhibitor-I (PAI-1) is the major active protein (15, 16) . The intricate balance between plasminogen activators and their inhibitors, therefore, tightly regulates fibrinolytic activity.
Vascular endothelial cells play a pivotal role in the regulation of fibrinolysis (17) . In addition to constituting a nonthrombogenic barrier between circulating blood and subendothelial components (18) , vascular endothelial cells produce and secrete integral proteins of the fibrinolytic cascade, such as tissue plasminogen activator and PAI-I (17) . Disturbance in the production of these components has been implicated in or correlated with thrombotic and hemorrhagic disease states including deep vein thrombosis (19, 20) , coronary artery disease (21, 22) , allograft rejection (23) , and inherited hemorrhagic disorders (24, 25) . In addition, the clinical utility of fibrinolytic regulation has been demonstrated by the widespread use of fibrinolytics such as tissue plasminogen activator for acute thrombotic events (26) (27) (28) .
Recent studies evaluating tissue plasminogen activator levels following cardiac allotransplantation have demonstrated that endothelial cell-derived tissue plasminogen activator is depleted after cardiac allotransplantation and this depletion correlates with graft failure (23) . On the basis of these studies, we have evaluated whether acute vascular rejection, which is characterized by diffuse intravascular thrombosis, might be associated with an aberrant balance of tissue plasminogen activator and plasminogen activator inhibitor-i, and whether this imbalance may be brought about by activation of small amounts of complement within the porcine-toprimate xenograft.
Materials and Methods
Grade L human fibrinogen, human glu-plasminogen, goat anti-porcine tissue plasminogen activator antibody, and goat anti-human plasminogen activator inhibitor-I antibody were purchased from American Diagnostica (Greenwich, CT). Plasminogen activator inhibitor-I was purchased from Calbiochem-Novabiochem International (La Jolla, CA), and flouresceinconjugated rabbit F(Ab')2 to goat IgG, from Or (29) . Serum was collected from normal pigs by routine venipuncture, and human serum was collected by venipuncture from normal human subjects. Following clotting of blood and centrifugation, all serum was stored at -80°C until ready for use. Human serum used in experiments was a pooled sample of equal proportion from four individuals. Fetal calf serum (FCS) was purchased from Hyclone (Salt Lake City, UT).
Tissue Specimens and Immunocytochemistry
Hearts from transgenic pigs expressing human complement proteins were transplanted into baboons as previously described (30) . The hearts were biopsied as previously described (8) washed with PBS and mounted. Tissue sections were examined using a Leitz DMRB epifluorescence microscope (Wetzlar, Germany). Immunofluorescence was graded on a scale of 0-4 (4 = maximum) by three independent reviewers. Background immunofluorescence was evaluated using tissue sections as described above but omitting the primary antibody. The specificity of antitissue plasminogen activator antibody was assessed in a blocking experiment in which tissue plasminogen activator (final concentration 2.9 jiM) was incubated with anti-porcine tissue plasminogen activator antibody (final concentration 1.3 ,uM) for 2 hr at room temperature, then applied to the tissue section. Antibody binding was tested by immunofluorescence as described above. The specificity of anti-plasminogen activator inhibitor-I antibody was assessed in a blocking experiment in which plasminogen activator inhibitor-I (final concentration 4.8 ,IM) was incubated with anti-human plasminogen activator inhibitor-I antibody (final concentration 1.3 ,uM) for 2 hr at room temperature, then applied to the tissue section. Antibody binding was evaluated and scored by immunofluorescence as described above.
Growth and Treatment of Porcine Aortic Endothelial Cells
Porcine aortic endothelial cells were isolated from freshly harvested aortae and grown in T-25 cell culture flasks in DMEM containing 20% autologous serum, L-glutamine (2.0 mM), penicillin (100 U/ml), and streptomycin (100 ,tg/ml). Cells were passed into 24-well plates (2 cm2) and grown to confluence in 5-8 days. Autologous porcine serum was removed, the cells were washed three times with PBS, and then were incubated with 20% human serum in DMEM for up to 24 hr. Control porcine aortic endothelial cells were incubated with autologous serum for the same times. After incubation, control or experimental medium was removed from the cells, serum-free medium was added, and the cells were incubated for 24 hr. The conditioned medium was then collected, concentrated 10-fold, and assayed for fibrinolytic activity. The harvested pool of cultured medium for each sample was 6 ml prior to concentration and assay.
Aortic endothelial cells were isolated from aortae of transgenic pigs expressing human CD59 and decay accelerating factor. The cells were grown in T-25 cell culture flasks in DMEM containing 10% FCS, L-glutamine (2.0 mM), penicillin (100 U/ml), and streptomycin (100 gg/ ml). Cells were passed into 24-well plates (2 cm2) and grown to confluence in 5-8 days. Control growth medium was removed, cells were washed with PBS, and incubated with 20% human serum for the same times as given above. Culture medium was collected and assayed as described below.
In Vitro Fibrinolytic Activity Assay Fibrin plates were prepared according to the methods of Soeda et al. (32) with the following modifications. Wells of 10 ,u volume were carved in the matrix using a 1-ml glass pipette tip. A 10-,lI sample of concentrated conditioned medium was placed in each well and the plate was incubated at 370C. After 18 hr of incubation, the area of lysis was calculated using the mean of 2 perpendicular diameters. Fibrinolytic activity was determined using a standard curve generated from human recombinant tissue plasminogen activator. Plasminogen activator inhibitor-I activity was determined using a standard curve of inhibition of tissue plasminogen activator by human recombinant plasminogen activator inhibitor- 1 minogen activator was located on vascular endothelium. Serial biopsies of porcine -hearts transplanted into baboons exhibited an initial increase in tissue plasminogen activator at 1 hr post-transplant, followed by a progressive decrease to background levels at 120 hr. Plasminogen activator inhibitor-1 was positive by immunofluorescence 1 hr post-transplant and increased progressively up to 216 hr post-transplant (Figs. 1, 2 (Fig. 3) .
To determine if the increase in antifibrinolytic activity in medium from cultured endothe- Hours After Transplantation was assessed. This medium, following the block of plasminogen activator inhibitor-i, contained fibrinolytic activity (Fig. 4) gested that inflammatory events activate vascu1ar endothelium leading to procoagulant changes that account for the dramatic extent of fibrin deposition and thrombosis in acute vascular rejection (34) . Experimental work from our laboratory and others has suggested that procoagulant activity seen in acute vascular might be caused by increased expression of tissue factor on vascular endothelium (35) and in inflammatory macrophages (36) , loss of endothelial-associated heparan sulfate (37) , and decreased availability and function of thrombomodulin (38, 39) . While these factors may contribute to increased generation of fibrin, the results of our study clearly demonstrate that there is also a fundamental disturbance in fibrinolysis owing to imbalance between tissue plasminogen activator and plasminogen activator inhibitor-I, resulting in a shift toward decreased fibrinolytic activity in porcineto-primate xenotransplantation. Thus, to the extent that thrombosis in a xenotransplant is caused by aberration in the fibrinolytic cascade, therapeutic strategies aimed at acute vascular rejection may have to address this defect as well. Current research supports the understanding that acute vascular rejection is associated with endothelial cell activation (1, 4) . In this report, we have attempted to establish what role alterations in the fibrinolytic system, as regulated by vascular endothelial cells and potentially arising in the context of endothelial cell activation, play in the process of acute vascular rejection. Our findings support the conclusion that changes in fibrinolysis might be involved in the pathogenesis of acute vascular rejection, rather than resulting as a consequence of tissue damage secondary to rejection because the increased expression of plasminogen activator inhibitor-l and decreased expression of tissue plasminogen activator seen in xenograft biopsies preceded histologic evidence of tissue damage caused by acute vascular rejection.
The in vitro system that was employed in our studies involved stimulation of porcine aortic endothelial cells by human serum as a model for the reaction that occurs when a xenograft undergoes acute vascular rejection (1, 37) . In this system, the increase in antifibrinolytic activity was due at least in part to increases in plasmin0gen activator inhibitor-I as antibodies against plasminogen activator-I blocked the increased inhibitory activity. The fact that transgenic porcine cells expressing human complement regulatory proteins did not exhibit increased antifibrinolytic activity following stimulation with dilute human serum in vitro supports the conclusion that the activation of human complement on porcine endothelial cells may be one of the key steps in this process. In this setting, it is likely that complement activation directly stimulates endothelial cells, resulting in increased production and secretion of plasminogen activator inhibitor-I and decreased production of tissue plasminogen activator, and thus altering the profibrinolytic state of the endothelial cells. This change in the fibrinolytic balance is likely one of the phenotypic events that leads to the thrombotic diathesis seen in acute vascular rejection. In considering this relationship between in vitro fibrinolysis and in vivo events, it is important to bear in mind that PAI-I exists in an active form and as an inactive protein. The functional analysis of endothelial cell responses tests only the active form of the protein whereas immunohistochemistry as performed in this study might detect inactive protein as well as active protein.
One should note that we observed a significant difference in the protective effect of the transgenic expression of CD59 and decay accelerating factor between our in vitro and in vivo data. The results observed from tissue biopsies from transgenic animals demonstrate a progressive shift from a fibrinolytic to an antifibrinolytic state over the first 72 hr of the transplant. This is in contrast to the observation in vitro where the transgenic cells provided complete protection from antifibrinolytic activity following treatment with human serum. Although there are many potential interpretations of these data, one likely explanation for this difference is that the complement regulatory proteins prevent complement activation in the in vitro system in which a low concentration of complement (20% human serum) was used. On the other hand, it is likely that the protective effect of these proteins is overwhelmed when the endothelial cells are exposed to the normal levels of complement present in vivo (9, 10) . Consistent with this concept is the observation of Cozzi and co-workers that acute vascular rejection can sometimes be avoided if the xenogeneic organ graft expresses high levels of DAF (unpublished). Furthermore, the in vivo transplant may also be exposed to other inflammatory stimuli in addition to complement activation. These other stimuli, such as cytokines secreted by inflammatory cells are not affected by complement regulatory proteins.
The changes in tissue plasminogen activator and plasminogen activator inhibitor-I expression may be explained by the following para-digm. Upon exposure to human xenoreactive natural antibodies and complement, vascular endothelial cells in the graft are activated, resulting in an initial increase in both tissue plasminogen activator and plasminogen activator inhibitor-i. As the major source of tissue plasminogen activator, endothelial cells contribute to the total pool of tissue plasminogen activator through two mechanisms. At first there occurs a release of tissue plasminogen activator from cellular stores (40) , secreted in response to stimuli such as shear stress (41) or thrombin (33, 42) . Initial stores are rapidly depleted and tissue plasminogen activator levels are reduced until an induced de novo synthesis occurs in 4-6 hr (40) . Because endothelial cells do not contain stores of plasminogen activator inhibitor-1, the production of this molecule and secretion are delayed relative to the response of tissue plasminogen activator. Therefore, the increased ratio of plasminogen activator inhibitor-I to tissue plasminogen activator, which impedes fibrinolysis, is delayed for a period of hours after endothelial cell activation. In addition, it has been shown that interleukin-1 a is up-regulated in response to endothelial cell activation by complement. In turn, interleukin 1 a suppresses the fibrinolytic system of endothelial cells by increasing activity of plasminogen activator inhibitor-i (43, 44) and decreasing activity of tissue plasminogen activator (43) . This hypothesis is supported by the results of this study (Figs. 1, 2) , which shows the course of the ratio of plasminogen activator inhibitor-I to tissue plasminogen activator expression.
In summary, the findings of this study support the conclusion that the fibrinolytic process is altered during the process of acute vascular xenograft rejection. This suggests that further scientific and clinical experimentation that alters the fibrinolytic state of the xenograft may benefit graft survival in the setting of porcine-to-primate xenotransplantation.
